Roxane Laboratories
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Roxane Laboratories sits in the top decile of US sponsors by registered trial count (#253 of 15,742 sponsors by registered trial count).
Roxane Laboratories: 93 sponsored US clinical trials, none currently recruiting.
Roxane Laboratories sponsors 93 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 92 completed. 2 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 4 trials.
Top-decile sponsor footprint
Roxane Laboratories ranks in the top decile of sponsors by registered trial count (#253 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
92 of 93 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (98.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
93 total, page 2 of 2
Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed Conditions
NCT00826787
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions
NCT00618202
Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions
NCT00618163
Bioequivalency Study of Meloxicam Tablets Under Fed Conditions
NCT00601887
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions
NCT00618254
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions
NCT00618111
Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed Conditions
NCT01102465
Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions
NCT01102478
Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions
NCT00702260
Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions
NCT00702091
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
NCT00618046
Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions
NCT01331434
Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions
NCT01216878
Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions
NCT00602524
Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions
NCT00618059
Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions
NCT01216852
Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
NCT01331421
Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
NCT01331447
Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions
NCT00602017
Bioequivalency Study of Amlodipine Tablets Under Fed Conditions
NCT00601302
Bioequivalency Study of Terbinafine Tablets Under Fed Conditions
NCT00602251
Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions
NCT00602719
Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
NCT00602342
Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions
NCT00601666
Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions
NCT00694317
Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions
NCT00602407
Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions
NCT00694187
Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions
NCT00618228
Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions
NCT00601211
Bioequivalency Study of Torsemide Tablets Under Fasting Conditions
NCT00602303
Bioequivalency Study of Torsemide Tablets Under Fed Conditions
NCT00602615
Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions
NCT00601874
Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions
NCT00601328
Bioequivalency Study of Zidovudine Under Fasting Conditions
NCT00602550
Bioequivalency Study of Zidovudine Under Fed Conditions
NCT00601562
Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions
NCT00602394
Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions
NCT00602173
Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions
NCT00601315
Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions
NCT00601536
Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions
NCT00602498
Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions
NCT00602381
Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions
NCT00602134
Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions
NCT00601575
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
How the Roxane Laboratories early-phase archive is shaped
93 indexed studies, none listed as recruiting (0% open); 92 completed (99%).
Phase mix: 2 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (4 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Roxane Laboratories: archived-pipeline peers nationwide
Peers matched on 93 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Roxane Laboratories sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 93 archived trials
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · 93 trials · 13% recruiting
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 93 trials · 17% recruiting
- Colorado State University · 94 trials · 21% recruiting
- Endeavor Health · 94 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Roxane Laboratories page
93 registered trials is a research-attention snapshot, not an endorsement of Roxane Laboratories or any single study.
- None of Roxane Laboratories's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Breast Cancer is the condition Roxane Laboratories studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Roxane Laboratories pipeline card: 93 registered trials from official public datasets.Report a data error.